Afficher la notice abrégée

dc.creatorSimantirakis E., Tsironis I., Vassilopoulos G.en
dc.date.accessioned2023-01-31T09:56:11Z
dc.date.available2023-01-31T09:56:11Z
dc.date.issued2020
dc.identifier10.3390/v12030332
dc.identifier.issn19994915
dc.identifier.urihttp://hdl.handle.net/11615/78982
dc.description.abstractHematopoietic Stem Cells (HSCs) are a unique population of cells, capable of reconstituting the blood system of an organism through orchestrated self-renewal and differentiation. They play a pivotal role in stem cell therapies, both autologous and allogeneic. In the field of gene and cell therapy, HSCs, genetically modified or otherwise, are used to alleviate or correct a genetic defect. In this concise review, we discuss the use of SFVpsc-huHSRV.13, formerly known as Prototype Foamy Viral (PFV or FV) vectors, as vehicles for gene delivery in HSCs. We present the properties of the FV vectors that make them ideal for HSC delivery vehicles, we review their record in HSC gene marking studies and their potential as therapeutic vectors for monogenic disorders in preclinical animal models. FVs are a safe and efficient tool for delivering genes in HSCs compared to other retroviral gene delivery systems. Novel technological advancements in their production and purification in closed systems, have allowed their production under cGMP compliant conditions. It may only be a matter of time before they find their way into the clinic. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.language.isoenen
dc.sourceVirusesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082255960&doi=10.3390%2fv12030332&partnerID=40&md5=2fba2568f42a54a9c732d3de2534c9cf
dc.subjectCD11 antigenen
dc.subjectCD18 antigenen
dc.subjectCD34 antigenen
dc.subjectcomplementary DNAen
dc.subjectcyclic GMPen
dc.subjectmessenger RNAen
dc.subjectpyruvate kinaseen
dc.subjectvirus vectoren
dc.subjectcell immortalizationen
dc.subjectDNA methylationen
dc.subjectDNA repairen
dc.subjectgene expressionen
dc.subjectgene mutationen
dc.subjectgene silencingen
dc.subjectgene targetingen
dc.subjectgene transferen
dc.subjectgranulomatosisen
dc.subjecthematopoietic stem cellen
dc.subjecthematopoietic stem cell transplantationen
dc.subjecthumanen
dc.subjectmonogenic disorderen
dc.subjectnonhumanen
dc.subjectnuclear localization signalen
dc.subjectopen reading frameen
dc.subjectprotein expressionen
dc.subjectReviewen
dc.subjectsize exclusion chromatographyen
dc.subjectSpumavirusen
dc.subjectanimalen
dc.subjectdisease modelen
dc.subjectgene therapyen
dc.subjectgene vectoren
dc.subjectgenetic transductionen
dc.subjectgeneticsen
dc.subjecthematopoietic stem cellen
dc.subjectmetabolismen
dc.subjectpreclinical studyen
dc.subjectSpumavirusen
dc.subjectAnimalsen
dc.subjectDisease Models, Animalen
dc.subjectDrug Evaluation, Preclinicalen
dc.subjectGene Transfer Techniquesen
dc.subjectGenetic Therapyen
dc.subjectGenetic Vectorsen
dc.subjectHematopoietic Stem Cellsen
dc.subjectHumansen
dc.subjectSpumavirusen
dc.subjectTransduction, Geneticen
dc.subjectMDPI AGen
dc.titleFV vectors as alternative gene vehicles for gene transfer in HSCsen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée